FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileRecce Pharmaceuticals Ltd
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
RCE.AX
Recce Pharmaceuticals Ltd Stock AnalysisComprehensive stock analysis for Recce Pharmaceuticals Ltd (RCE.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisRCE.AX
RCE.AX
Recce Pharmaceuticals Ltd
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
RCE.AX
  1. Home
  2. Stocks
  3. Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd

🇦🇺RCE.AX•ASX

Recce Pharmaceuticals Ltd

🇦🇺RCE.AX•ASX

Your view on RCE.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Recce Pharmaceuticals Ltd

Industry
Biotechnology
Sector
Healthcare
CEO
James Hamilton-Bray Graham
Headquarters
Governor Macquarie Tower, Sydney, NSW, AU
Industry
Biotechnology
Sector
Healthcare
CEO
James Hamilton-Bray Graham
Headquarters
Governor Macquarie Tower, Sydney, NSW, AU
Description

Recce Pharmaceuticals Ltd operates as a biotechnology enterprise, concentrating on the research, advancement, and market introduction of synthetic anti-infective treatments across Australia, the United States, and the United Kingdom.

The company's foremost developmental drug, RECCE 327, is intended to address blood infections and sepsis caused by E. coli and S. aureus bacteria, including their antibiotic-resistant variants.

Additionally, Recce is progressing RECCE 529, a synthetic anti-infective targeting viral illnesses, and RECCE 435, another synthetic polymer anti-infective. Founded in 2007, the firm, which was initially named Recce Limited, officially became Recce Pharmaceuticals Ltd in November 2017. Its corporate headquarters are situated in Sydney, Australia.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Recce Pharmaceuticals Ltd. Starting points for Recce Pharmaceuticals Ltd: EPS -AUD 0.05, beta 0.39 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Recce Pharmaceuticals Ltd. Recce Pharmaceuticals Ltd does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Recce Pharmaceuticals Ltd. Trailing twelve-month EPS for Recce Pharmaceuticals Ltd stands at -AUD 0.05. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026
More →

Earnings per share estimates

Per shareThis yearYear to Jun 2027Next yearYear to Jun 2028
Average estimate−AUD 0.09−AUD 0.09
Lowest estimate−AUD 0.14−AUD 0.20
Highest estimate−AUD 0.04AUD 0.02
Number of analysts22
A year ago−AUD 0.05—
Growth vs a year ago−74.1%—

Revenue estimates

TotalThis yearYear to Jun 2027Next yearYear to Jun 2028
Average estimateAUD 3.39MAUD 19.21M
Lowest estimateAUD 2.92MAUD 18.61M
Highest estimateAUD 3.86MAUD 19.82M
Number of analysts21
A year agoAUD 0.00—
Growth vs a year ago——

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Recce Pharmaceuticals Ltd. Recce Pharmaceuticals Ltd has reported as a listed company since 2016. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold RCE.AX16 companies
Compare RCE.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
BIT.AXBiotron LimitedHealthcareBiotechnology—
BOT.AXBotanix Pharmaceuticals LimitedHealthcareBiotechnology—
ILA.AXIsland Pharmaceuticals LimitedHealthcareBiotechnology—
IMC.AXImmuron LimitedHealthcareBiotechnology—
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PRQRProQR Therapeutics N.V.HealthcareNASDAQ$155.2M
PRRUFImmutep LimitedHealthcareOTC$368.0M
PRTAProthena Corporation plcHealthcareNASDAQ$428.8M
PRTCYPureTech Health plcHealthcareOTC—
PRVCFPreveCeutical Medical Inc.HealthcareOTC$10.1M
PSYBFPsyBio Therapeutics Corp.HealthcareOTC$1,275
PTCHFPureTech Health plcHealthcareOTC$410.4M
PTCTPTC Therapeutics, Inc.HealthcareNASDAQ$5.0B
PTGXProtagonist Therapeutics, Inc.HealthcareNASDAQ$8.3B
PTHSPelthos Therapeutics Inc.HealthcareAMEX$27.9M
PTIXProtagenic Therapeutics, Inc.HealthcareNASDAQ$470,654
PTNPalatin Technologies, Inc.HealthcareNASDAQ$9.2M
Open Comparable Analysis
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Recce Pharmaceuticals Ltd. Coverage tracks Recce Pharmaceuticals Ltd within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Recce Pharmaceuticals Ltd.

RCE.AX AnalysisWeak
Past
1
Growth
1
Health
1
Profit
1
Value
1